Anti-obesity medications (AOMs) have not been studied in survivors of adolescent and young adult (AYA) cancer. In this retrospective analysis, generalized additive mixed model with penalized spline described body mass index (BMI) over time among survivors of AYA cancer prescribed an AOM. Body weight and BMI at pre-AOM maximum and last follow-up were summarized, with 95% confidence intervals. Over a median follow-up time of 249 days, 63.4% of survivors had ≥5% weight reduction. The proportion of survivors with severe obesity decreased from 60% to 35%. These findings suggest that AOMs are effective for weight reduction in survivors of AYA cancer.
ShimonyS, FlamandY, ValtisYK, et al.Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv, 2023; 7(18):5234–5245; doi: 10.1182/bloodadvances.2023009976
3.
TaiE, BuchananN, TownsendJ, et al.Health status of adolescent and young adult cancer survivors. Cancer, 2012; 118(19):4884–4891; doi: 10.1002/cncr.27445
4.
FlegalKM, CarrollMD, OgdenCL, et al.Prevalence and trends in obesity among US adults, 1999-2000. JAMA, 2002; 288(14):1723–1727; doi: 10.1001/jama.288.14.1723
5.
DietzWH. Health consequences of obesity in youth: Childhood predictors of adult disease. Pediatrics, 1998; 101(3 Pt 2):518–525.
6.
ChaoC, BhatiaS, XuL, et al.Chronic comorbidities among survivors of adolescent and young adult cancer. J Clin Oncol, 2020; 38(27):3161–3174; doi: 10.1200/JCO.20.00722
7.
ArmstrongGT, OeffingerKC, ChenY, et al.Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol, 2013; 31(29):3673–3680; doi: 10.1200/JCO.2013.49.3205
8.
MokeDJ, HamiltonAS, ChehabL, et al.Obesity and risk for second malignant neoplasms in childhood cancer survivors: A case-control study utilizing the California cancer registry. Cancer Epidemiol Biomarkers Prev, 2019; 28(10):1612–1620; doi: 10.1158/1055-9965.EPI-19-0466
9.
GrunvaldE, ShahR, HernaezR, et al.; AGA Clinical Guidelines Committee. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology, 2022; 163(5):1198–1225; doi: 10.1053/j.gastro.2022.08.045
10.
WeissT, YangL, CarrRD, et al.Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Res Care, 2022; 10(1); doi: 10.1136/bmjdrc-2021-002517
11.
CarlsGS, TanR, ZhuJY, et al.Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence. Obes Sci Pract, 2017; 3(3):342–351; doi: 10.1002/osp4.116
12.
AgrestiA, CoullBA. Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat, 1998; 52(2):119–126; doi: 10.2307/2685469
13.
WoodSN. Generalized Additive Models: An Introduction with R. Chapman and Hall/CRC; 2017.
14.
BarneaD, RaghunathanN, FriedmanDN, et al.Obesity and metabolic disease after childhood cancer. Oncology (Williston Park), 2015; 29(11):849–855.
15.
MulrooneyDA, YeazelMW, KawashimaT, et al.Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the childhood cancer survivor study cohort. Bmj, 2009; 339:b4606; doi: 10.1136/bmj.b4606
16.
MuellerS, FullertonHJ, StrattonK, et al.Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: A report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys, 2013; 86(4):649–655; doi: 10.1016/j.ijrobp.2013.03.034
17.
GibsonTM, LiZ, GreenDM, et al.Blood pressure status in adult survivors of childhood cancer: A report from the St. Jude lifetime cohort study. Cancer Epidemiol Biomarkers Prev, 2017; 26(12):1705–1713; doi: 10.1158/1055-9965.EPI-17-0510
18.
BessesenDH, Van GaalLF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol, 2018; 6(3):237–248; doi: 10.1016/S2213-8587(17)30236-X
19.
WildingJPH, BatterhamRL, CalannaS, et al.; STEP 1 Study Group. Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med, 2021; 384(11):989–1002; doi: 10.1056/NEJMoa2032183
20.
BrownJD, BuscemiJ, MilsomV, et al.Effects on cardiovascular risk factors of weight losses limited to 5-10. Transl Behav Med, 2016; 6(3):339–346; doi: 10.1007/s13142-015-0353-9
21.
ZomerE, GurusamyK, LeachR, et al.Interventions that cause weight loss and the impact on cardiovascular risk factors: A systematic review and meta-analysis. Obes Rev, 2016; 17(10):1001–1011; doi: 10.1111/obr.12433
22.
RyanDH, YockeySR. Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Curr Obes Rep, 2017; 6(2):187–194; doi: 10.1007/s13679-017-0262-y
23.
DixonSB, WangF, LuL, et al.Prediabetes and associated risk of cardiovascular events and chronic kidney disease among adult survivors of childhood cancer in the St Jude lifetime cohort. J Clin Oncol, 2024; 42(9):1031–1043; doi: 10.1200/JCO.23.01005
